MedTrace Logo

Long-Term Follow-up Study of ADVM-043

NCT03804021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2024-09-20

Study results available
· View outcomes & findings →

Summary

ADVM-043-03 is a long-term follow-up (LTFU) study of subjects who participated in the ADVM-043-01 (NCT02168686) multi-center gene therapy clinical study (ADVANCE) that evaluated ADVM-043 for the treatment of Alpha-1 Antitrypsin (A1AT) deficiency.

Conditions

  • Alpha-1 Antitrypsin Deficiency

Interventions

GENETIC

No Intervention

Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)

Sponsors & Collaborators

  • Adverum Biotechnologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Charlton Strange, MD · Medical University of South Carolina, Charleston, SC, USA

  • Mark Brantly, MD · University of Florida, Gainesville, FL, USA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-27
Primary Completion
2021-12-06
Completion
2021-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03804021 on ClinicalTrials.gov